References
- American Psychiatric Association (APA). 2000. Diagnostic and statistical manual of mental disorder. 4th ed. Text revision (DSM-IV-TR). Washington (DC): American Psychiatric Press.
- American Psychiatric Association (APA). 2013. Diagnostic and statistical manual of mental disorders (DSM-5). 5th ed. Washington (DC): American Psychiatric Press.
- Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. 2005. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 162:441–449. doi:https://doi.org/10.1176/appi.ajp.162.3.441
- Ascher-Svanum H, Novick D, Haro JM, Bertsch J, McDonnell D, Detke H. 2014. Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection. Neuropsychiatr Dis Treat. 10:1125–1131.
- Awad AG, Voruganti LNP. 2013. The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia. CNS Drugs. 27:625–636. doi:https://doi.org/10.1007/s40263-013-0070-1
- Bowie CR, Twamley EW, Anderson H, Halpern B, Patterson TL, Harvey PD. 2007. Self-assessment of functional status in schizophrenia. J Psychiatr Res. 41:1012–1018. doi:https://doi.org/10.1016/j.jpsychires.2006.08.003
- Brekke JS, Levin S, Wolkon GH, Sobel E, Slade E. 1993. Psychosocial functioning and subjective experience in schizophrenia. Schizophr Bull. 19:599–608. doi:https://doi.org/10.1093/schbul/19.3.599
- Brugnoli R, Rapinesi C, Kotzalidis GD, Marcellusi A, Mennini FS, De Filippis S, Carrus D, Ballerini A, Francomano A, Ducci G, et al. 2016. Model of Management (Mo.Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs). Riv Psichiatr. 51:47–59. doi:https://doi.org/10.1708/2246.24194
- Carmona VR, Gómez-Benito J, Huedo-Medina TB, Rojo JE. 2017. Employment outcomes for people with schizophrenia spectrum disorder: a meta-analysis of randomized controlled trials. Int J Occup Med Environ Health. 30:345–366. doi:https://doi.org/10.13075/ijomeh.1896.01074
- Chen R, Liou TH, Miao NF, Chang KH, Yen CF, Liao HF, et al. 2020. Using World Health Organization Disability Assessment Schedule 2.0 in people with schizophrenia: a 4-year follow-up. Eur Arch Psychiatry Clin Neurosc. 270:301–310.
- Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, Kane JM. 2016. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 77:1–24. doi:https://doi.org/10.4088/JCP.15032su1
- Dan A, Kumar S, Avasthi A, Grover S. 2011. A comparative study on quality of life of patients of schizophrenia with and without depression. Psychiatry Res. 189:185–189. doi:https://doi.org/10.1016/j.psychres.2011.02.017
- DeRosse P, Nitzburg GC, Blair M, Malhotra AK. 2018. Dimensional symptom severity and global cognitive function predict subjective quality of life in patients with schizophrenia and healthy adults. Schizophr Res. 195:385–390. doi:https://doi.org/10.1016/j.schres.2017.10.018
- Di Lorenzo R, Ferri P, Cameli M, Rovesti S, Piemonte C. 2019. Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting. NDT. 15:183–198. doi:https://doi.org/10.2147/NDT.S189245
- Doyle M, Flanagan S, Browne S, Clarke M, Lydon D, Larkin C, O'Callaghan E. 1999. Subjective and external assessments of quality of life in schizophrenia: relationship to insight. Acta Psychiatr Scand. 99:466–472. doi:https://doi.org/10.1111/j.1600-0447.1999.tb00994.x
- Eli Lilly and Company. 2012. ZypAdhera. Summary of product characteristics. EU.
- Emsley R, Chiliza B, Asmal L. 2013. The evidence for illness progression after relapse in schizophrenia. Schizophr Res. 148:117–121. doi:https://doi.org/10.1016/j.schres.2013.05.016
- Endicott J, Spitzer R, Fleiss JL, Cohen J. 1976. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 33:766–771. doi:https://doi.org/10.1001/archpsyc.1976.01770060086012
- Fang SC, Liao DL, Huang CY, Hsu CC, Cheng SL, Shao YHJ. 2020. The effectiveness of long-acting injectable antipsychotics versus oral antipsychotics in the maintenance treatment of outpatients with chronic schizophrenia. Hum. Psychopharmacol. 35:e2729.
- Federici S, Bracalenti M, Meloni F, Luciano JV. 2017. World Health Organization disability assessment schedule 2.0: an international systematic review. Disabil Rehabil. 39:2347–2380. doi:https://doi.org/10.1080/09638288.2016.1223177
- First MB, Spitzer RL, Gibbon M, Williams JBW. 2002. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, research version, patient edition (SCID-I/P). New York (NY): Biometrics Research, New York State Psychiatric Institute.
- Galderisi S, Rossi A, Rocca P, Bertolino A, Mucci A, Bucci P, Rucci P, Gibertoni D, Aguglia E, Amore M, et al., Italian Network For Research on Psychoses. 2014. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry. 13:275–287. doi:https://doi.org/10.1002/wps.20167
- Gold LH. 2014. DSM-5 and the assessment of functioning: the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0). J Am Acad Psychiatry Law. 42:173–181.
- Gspandl S, Peirson RP, Nahhas RW, Skale TG, Lehrer DS. 2018. Comparing global assessment of functioning (GAF) and World Health Organization disability assessment schedule (WHODAS) 2.0 in schizophrenia. Psychiatry Res. 259:251–253. doi:https://doi.org/10.1016/j.psychres.2017.10.033
- Guilera G, Gómez-Benito J, Pino O, Rojo JE, Cuesta MJ, Martínez-Arán A, Safont G, Tabarés-Seisdedos R, Vieta E, Bernardo M, et al. 2012. Utility of the World Health Organization Disability Assessment Schedule II in schizophrenia. Schizophr Res. 138:240–247. doi:https://doi.org/10.1016/j.schres.2012.03.031
- Haddad PM, Kishimoto T, Correll CU, Kane JM. 2015. Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance. Curr Opin Psychiatry. 28:216–221. doi:https://doi.org/10.1097/YCO.0000000000000160
- Harvey PD, Bellack AS. 2009. Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept? Schizophr Bull. 35:300–306. doi:https://doi.org/10.1093/schbul/sbn171
- Hawley CJ, Gale TM, Sivakumaran T, Hertfordshire N. R g. 2002. Defining remission by cut off score on the MADRS: selecting the optimal value. J. Affect. Disord. 72:177–184. doi:https://doi.org/10.1016/S0165-0327(01)00451-7
- Hayhurst KP, Drake RJ, Massie JA, Dunn G, Barnes TRE, Jones PB, Lewis SW. 2014. Improved quality of life over one year is associated with improved adherence in patients with schizophrenia. Eur Psychiatry. 29:191–196. doi:https://doi.org/10.1016/j.eurpsy.2013.03.002
- Jääskeläinen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, Veijola J, Miettunen J. 2013. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 39:1296–1306. doi:https://doi.org/10.1093/schbul/sbs130
- Janssen-Cilag. 2012. Xeplion. Summary of product characteristics. EU.
- Jin H, Zisook S, Palmer BW, Patterson TL, Heaton RK, Jeste DV. 2001. Association of depressive symptoms and functioning in schizophrenia: a study in older outpatients. J Clin Psychiatry. 62:797–803. doi:https://doi.org/10.4088/JCP.v62n1008
- Kane JM, Kishimoto T, Correll CU. 2013. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 12:216–226. doi:https://doi.org/10.1002/wps.20060
- Kaplan G, Casoy J, Zummo J. 2013. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 7:1171–1180. doi:https://doi.org/10.2147/PPA.S53795
- Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 13:261–276. doi:https://doi.org/10.1093/schbul/13.2.261
- Kayes NM, McPherson KM. 2010. Measuring what matters: does ‘objectivity’ mean good science? Disabil Rehabil. 32:1011–1019. doi:https://doi.org/10.3109/09638281003775501
- Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A, Wagner T, Czekalla J. 2006. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry. 67:1690–1697. doi:https://doi.org/10.4088/jcp.v67n1104
- Leonardi M, Bickenbach J, Üstün TB, Kostanjsek N, Chatterji S. 2006. The definition of disability: what is in a name? Lancet. 368:1219–1221. doi:https://doi.org/10.1016/S0140-6736(06)69498-1
- Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. 2005. What does the PANSS mean? Schizophr Res. 79:231–238. doi:https://doi.org/10.1016/j.schres.2005.04.008
- Liberman RP, Kopelowicz A, Ventura J, Gutkind D. 2002. Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiatry. 14:256–272. doi:https://doi.org/10.1080/0954026021000016905
- Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L. 2013. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 13:340. doi:https://doi.org/10.1186/1471-244X-13-340
- Longden E, Read J. 2016. Assessing and reporting the adverse effects of antipsychotic medication: a systematic review of clinical studies, and prospective, retrospective, and cross-sectional research. Clin Neuropharmacol. 39:29–39. doi:https://doi.org/10.1097/WNF.0000000000000117
- Lukasiewicz M, Gerard S, Besnard A, Falissard B, Perrin E, Sapin H, Tohen M, Reed C, Azorin JM, Emblem Study Group. 2013. Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort. Int J Methods Psychiatr Res. 22:46–58. doi:https://doi.org/10.1002/mpr.1379
- Montgomery SA, Asberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry. 134:382–389. doi:https://doi.org/10.1192/bjp.134.4.382
- Müller MJ, Himmerich H, Kienzle B, Szegedi A. 2003. Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). J. Affect. Disord. 77:255–260. (02)00120-9 doi:https://doi.org/10.1016/S0165-0327(02)00120-9
- Naber D. 2008. Subjective effects of antipsychotic drugs and their relevance for compliance and remission. Epidemiol Psichiatr Soc. 17:174–176. doi:https://doi.org/10.1017/s1121189x00001238
- Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, Andresen B, Rajonk F. 2001. Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res. 50:79–88. doi:https://doi.org/10.1016/S0920-9964(00)00166-3
- Olagunju AT, Clark SR, Baune BT. 2019. Long-acting atypical antipsychotics in schizophrenia: a systematic review and meta-analyses of effects on functional outcome. Aust N Z J Psychiatry. 53:509–527. doi:https://doi.org/10.1177/0004867419837358
- Otsuka Pharmaceutical. 2013. Abilify Maintena. Summary of product characteristics. EU.
- Pietrini F, Albert U, Ballerini A, Calò P, Maina G, Pinna F, Vaggi M, Boggian I, Fontana M, Moro C, et al. 2019. The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia. Neuropsychiatr Dis Treat. 15:1045–1060. doi:https://doi.org/10.2147/NDT.S199048
- Pietrini F, D'Anna G, Tatini L, Talamba GA, Andrisano C, Calderani E, Manetti M, Rossi Prodi P, Ricca V, Ballerini A, et al. 2018. Changes in attitude towards LAI antipsychotic maintenance treatment: a two-year follow-up study. Eur Psychiatry. 53:58–65. doi:https://doi.org/10.1016/j.eurpsy.2018.06.002
- Pietrini F, Spadafora M, Talamba GA, Godini L, Lelli L, Arcabasso S, Manetti M, Ballerini A. 2015. The effects of switching from oral to LAI antipsychotic treatment on subjective experience of schizophrenic and schizoaffective patients: preliminary results. Int J Psychiatry Clin Pract. 19:106–113. doi:https://doi.org/10.3109/13651501.2014.988268
- Pietrini F, Spadafora M, Tatini L, Talamba GA, Andrisano C, Boncompagni G, Manetti M, Ricca V, Ballerini A. 2016. LAI versus oral: a case-control study on subjective experience of antipsychotic maintenance treatment. Eur Psychiatry. 37:35–42. doi:https://doi.org/10.1016/j.eurpsy.2016.05.008
- Rocca P, Montemagni C, Frieri T. 2016. Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life. Neuropsychiatr Dis Treat. 12:917–929. doi:https://doi.org/10.2147/NDT.S88632
- Rossi A, Galderisi S, Rocca P, Bertolino A, Mucci A, Rucci P, Gibertoni D, Aguglia E, Amore M, Andriola I, et al., Italian Network for Research on Psychoses. 2017. The relationships of personal resources with symptom severity and psychosocial functioning in persons with schizophrenia: results from the Italian Network for Research on Psychoses study. Eur Arch Psychiatry Clin Neurosci. 267:285–294. doi:https://doi.org/10.1007/s00406-016-0710-9
- Sartorius N. 2009. Disability and mental illness are different entities and should be assessed separately. World Psychiatry. 8:86. doi:https://doi.org/10.1002/j.2051-5545.2009.tb00220.x
- Schrank B, Bird V, Tylee A, Coggins T, Rashid T, Slade M. 2013. Conceptualising and measuring the well-being of people with psychosis: systematic review and narrative synthesis. Soc Sci Med. 92:9–21. doi:https://doi.org/10.1016/j.socscimed.2013.05.011
- Sheehan JJ, Reilly KR, Fu DJ, Alphs L. 2012. Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. Innov Clin Neurosci. 9:17–23. PMID: 22984648
- Sjonnesen K, Bulloch AGM, Williams J, Lavorato D, Patten SB. 2016. Characterization of Disability in Canadians with Mental Disorders Using an Abbreviated Version of a DSM-5 Emerging Measure: The 12-Item WHO Disability Assessment Schedule (WHODAS) 2.0. Can J Psychiatry. 61:227–235. doi:https://doi.org/10.1177/0706743716632514
- Stahl SM. 2014. Long-acting injectable antipsychotics: shall the last be first? CNS Spectr. 19:3–5. doi:https://doi.org/10.1017/S1092852913001016
- Stevens GL, Dawson G, Zummo J. 2016. Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia. Early Interv Psychiatry. 10:365–377. doi:https://doi.org/10.1111/eip.12278
- Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtälä J, Hoti F, Jedenius E, Enkusson D, Leval A, Sermon J, Tanskanen A, et al. 2017. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 74:686–693. doi:https://doi.org/10.1001/jamapsychiatry.2017.1322
- Ustün TB, Chatterji S, Kostanjsek N, Rehm J, Kennedy C, Epping-Jordan J, Saxena S, von Korff M, Pull C, WHO/NIH Joint Project. 2010. Developing the World Health Organization disability assessment schedule 2.0. Bull World Health Organ. 88:815–823. doi:https://doi.org/10.2471/BLT.09.067231
- Üstün TB, World Health Organization. 2010. Measuring health and disability: manual for WHO Disability Assessment Schedule WHODAS-2.0. Geneva (Switzerland): World Health Organization.
- van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L, Bernardo M, Arango C, Fleischhacker W, Lachaux B, et al. 2006. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand. 113:91–95. doi:https://doi.org/10.1111/j.1600-0447.2005.00659.x
- van Os J, Kapur S. 2009. Schizophrenia. Lancet. 374:635–645. doi:https://doi.org/10.1016/S0140-6736(09)60995-8
- Vita A, Barlati S. 2018. Recovery from schizophrenia: is it possible? Curr Opin Psychiatry. 31:246–255. doi:https://doi.org/10.1097/YCO.0000000000000407
- Ware JE, Snow K, Kosinski M, Gamdek B. 1997. SF-36 health survey manual and interpretation guide. Boston (MA): The Health Institute, New England Medical Center.
- Watson P, Zhang JP, Rizvi A, Tamaiev J, Birnbaum ML, Kane J. 2018. A meta-analysis of factors associated with quality of life in first episode psychosis. Schizophr. Res. 202:26–36. doi:https://doi.org/10.1016/j.schres.2018.07.013
- Wiersma D, Wanderling J, Dragomirecka E, Ganev K, Harrison G, An Der Heiden W, Nienhuis FJ, Walsh D. 2000. Social disability in schizophrenia: its development and prediction over 15 years in incidence cohorts in six European centres. Psychol Med. 30:1155–1167. doi:https://doi.org/10.1017/s0033291799002627
- Witte MM, Case MG, Schuh KJ, Ascher-Svanum H. 2012. Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia. Curr. Med. Res. Opin. 28:315–323. doi:https://doi.org/10.1185/03007995.2012.657300
- World Health Organization (WHO). 2000. World Health Organization: Disability Assessment Schedule II (WHO-DAS II). Geneva (Switzerland): WHO.
- World Health Organization (WHO). 2002. Towards a common language for functioning, disability and health: ICF. The International Classification of Functioning, Disability and Health. Geneva (Switzerland): WHO. [cited 2021 Mar 4]. http://www.who.int/classifications/icf/training/icfbeginnersguide.pdf
- Young RC, Biggs JT, Ziegler VE, Meyer DA. 1978. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 133:429–435. doi:https://doi.org/10.1192/bjp.133.5.429